Evaluation of renal safety between Imipenem/Relebactam and Colistin Plus Imipenem in patients with Imipenem-nonsusceptible bacterial infections in the randomized, phase 3 RESTORE-IMI 1 study

AbstractBackground. In the randomized controlled RESTORE-IMI 1 clinical trial (NCT02452047), imipenem/cilastatin (IMI) with relebactam (IMI/REL) was as effecti

Saved in:

Bibliographic Details
Main Authors:	Brown, Michelle L. (Author) , Motsch, Johann (Author) , Kaye, Keith S. (Author) , File, Thomas M. (Author) , Boucher, Helen W. (Author) , Vendetti, Neika (Author) , Aggrey, Angela (Author) , Joeng, Hee-Koung (Author) , Tipping, Robert W. (Author) , Du, Jiejun (Author) , DePestel, Daryl D. (Author) , Butterton, Joan R. (Author) , Paschke, Amanda (Author)
Format:	Article (Journal)
Language:	English
Published:	[2020]
In:	Open Forum Infectious Diseases Year: 2020, Volume: 7, Issue: 3
ISSN:	2328-8957
DOI:	10.1093/ofid/ofaa054
Online Access:	Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1093/ofid/ofaa054 Verlag, lizenzpflichtig, Volltext: https://academic.oup.com/ofid/article/7/3/ofaa054/5740221
Author Notes:	Michelle L. Brown, Johann Motsch, Keith S. Kaye, Thomas M. File, Helen W. Boucher, Neika Vendetti, Angela Aggrey, Hee-Koung Joeng, Robert W. Tipping, Jiejun Du, Daryl D. DePestel, Joan R. Butterton, and Amanda Paschke

Description
Summary:	AbstractBackground. In the randomized controlled RESTORE-IMI 1 clinical trial (NCT02452047), imipenem/cilastatin (IMI) with relebactam (IMI/REL) was as effecti
Item Description:	Gesehen am 21.04.2020
Physical Description:	Online Resource
ISSN:	2328-8957
DOI:	10.1093/ofid/ofaa054